Monday, February 16, 2026 2/16/2026

RAPID KINASE PROFILING WITH LUMINESCENT REPORTERS

Award Number: R43GM087807
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/29/2010
PERIOD OF PERFORMANCE END DATE: 02/28/2011

Group Awards By:

View Award Description

RAPID KINASE PROFILING WITH LUMINESCENT REPORTERS - DESCRIPTION (provided by applicant): More than 500 different protein kinases have been identified in humans and represent 1.7% of the human genome. Protein kinases function by catalyzing the transfer of the 3-phosphoryl group of ATP to the hydroxyl group on a specific protein substrate. The central role of kinases in disease and their fundamental role in human biology have prompted the development of potent and selective inhibitors as therapeutic agents and as novel tools for dissecting kinase function in the context of signal transduction pathways. Because many human kinases are so closely related both genetically and structurally, many inhibitors lack specificity for a single target and act on more than one kinase, typically by out-competing ATP in the active site. Hence there is a need for comprehensive kinase panels and tools for selectivity assessment of drugs. The kinase screening and profiling market was estimated to be $106 MM in 2008 and the demand is steadily rising every year. The purpose of our application is to develop a luminescence-based, homogeneous, non- radioactive, sensitive, cell-free assay that can be rapidly adapted for high throughput (HTP) screening and profiling of small molecule antagonists of kinases. The utility of this assay against commercially available drugs/dug candidates and the selectivity of these molecules against a kinase panel will be demonstrated. PUBLIC HEALTH RELEVANCE: Kinases constitute 1.7% of the genome and are implicated in various diseases, from cancer to diabetes. Assessment of selectivity of drugs against kinases is critical to evaluate their physiological safety. The purpose of our application is to develop a method to identify selective drugs by profiling them against a kinase panel.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = $45,000 )
2010	2010	LUCEOME BIOTECHNOLOGIES LLC	3938 EAST GRANT ROAD	TUCSON	AZ	85712	PIMA	USA	Trans-NIH Recovery Act Research Support	000	1	1/22/2010	SUPPLEMENT FOR EXPANSION	$45,000
														Subtotal = $45,000

Issue Date FY: 2009 ( Subtotal = $135,886 )
2009	2009	LUCEOME BIOTECHNOLOGIES LLC	3938 EAST GRANT ROAD	TUCSON	AZ	85712	PIMA	USA	Biomedical Research and Research Training	000	1	8/10/2009	NEW	$135,886
														Subtotal = $135,886

Grand Total All Awards = $180,886

Top

All Categories

About

Search

Reports

Data Submission

Award Information

RAPID KINASE PROFILING WITH LUMINESCENT REPORTERS

Award Number: R43GM087807

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/29/2010

PERIOD OF PERFORMANCE END DATE: 02/28/2011

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer